The extent of dosage reduction recommended for patients with intermediate activity in both enzymes is currently not clear. Mercaptopurine dosages during maintenance were collected from 1768 patients with acute lymphoblastic leukemia in Singapore, Guatemala, India, and North America.
[JNCI-Journal Of The National Cancer Institute]